Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal fluid BAT monitoring during birch pollen allergen immunotherapy in allergic rhinitis
NL-OMON52036Completed
- Sponsor
- Rijnstate
- Start
- Sep 2023
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of allergenic extract of birch in allergic rhinitis (AR) and birch pollen allergy (2 arms), sponsored by Rijnstate. Primary endpoint: Comparison of nasal fluid BAT and serum BAT inhibition over time. Started Sep 2023; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinitis (AR)birch pollen allergy
Beyond the preview
Go deeper on NL-OMON52036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52036.